CordIng Jerry Pharmaceuticals - B: KN026 new drug application for marketing approved by the National Medical Products Administration.

announcement by CStone Pharmaceuticals - The company's new drug KN026, developed in collaboration with Shanghai Junmant Bio-technology Co., Ltd., an affiliate of Shiyao Group Co., Ltd., for the treatment of locally advanced, recurrent, or metastatic HER2-positive gastric/gastroesophageal junction adenocarcinoma in patients who have received at least one prior systemic therapy, has been accepted for market application by the China National Medical Products Administration. Currently, there are no approved anti-HER2 drugs for second-line treatment of HER2-positive gastric cancer. KN026 is the first dual-specificity anti-HER2 antibody drug to show positive results in second-line treatment of gastric cancer in China.